SAB Biotherapeutics Inc. (SABS) exhibits 45.0% gross margins and -27.4% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 22.1x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into — operating margin and -27.4% ROIC, outpacing sector cost of capital.
ROIC: -27.4% // GM: 45.0%YoY revenue trajectory of — paired with -15.55% free cash flow yield supports self-funded R&D and capital return.
REV YOY: — // FCF YLD: -15.55%Altman Z-Score of 7.07 and Piotroski F-Score of 3/9 indicate low near-term refinancing stress.
ALTMAN Z: 7.07 // F-SCORE: 3/9Trading at 22.1x trailing P/E (20.6x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 22.1x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $3.30 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend — net margins.
NET MARGIN: — // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for SABS & activate live FRED threshold breach alerts.